The Sugarfree Day 2024 a success!

2024.10.12

Wrapping up this year's Sugarfree Day, we conclude we had a sold out A-huset and many more online. The adjacent exhibition displayed all aspects of metabolic health initiatives, including our own Metabolic Screening, Acetrack and book sales (that sold out!)

Ringing the bell at Nasdaq!

2024.09.06

What a day for us all - thanks for everyone involved throughout the years!

Distribution agreement with Belgian digital pharmacy Newpharma

2024.08.20

Uppsala, 20240820 — Deversify Health AB (publ) ("Deversify"), which was recently listed on Nasdaq First North through a reverse acquisition, has signed a distribution agreement with Belgian pharmacy chain Newpharma SRL ("Newpharma") and their subsidiary Smart Value Distribution SRL for resale of Acetrack in central Western Europe. As far as resellers are concerned, Deversify currently only has such dealers in Sweden and offers Acetrack in the rest of Europe and the world exclusively through its own channels. The agreement with Newpharma means that two new milestones are achieved: part resale in central Europe and part distribution to end customers through digital and physical pharmacies. Newpharma is a fast-growing pharmacy chain with e-commerce in France, Belgium, the Netherlands, Luxembourg, Germany, Austria and Switzerland and was among other things voted France's best e-pharmacy in 2023. Their distribution company also delivers to other pharmacies around the region, in in most cases physical pharmacies. Newpharma also has a close connection with Yooboo, which is a Belgian opinion leader around the importance of lifestyle changes. "The fact that we are starting to find local sales channels and logistics partners out in continental Europe is a good sign that the demand for solutions such as Acetrack offers is rising," says Anders Murman, CEO of Deversify. "The fact that it also comes from an actor such as Newpharma, with a modern approach to lifestyle changes and which tries to change how the pharmacy's role in society can become more holistic, is gratifying as it is completely in line with Deversify's view of how health improvements can be achieved without necessarily always rely on medicine."

Conditional approval received from Nasdaq for re-listing at First North

2024.07.09

Read more in the press releases segment (in Swedish)

SPA for reverse take-over of Euroafrica Digital Ventures announced

2024.02.29

Read more in the press release segment (in Swedish)

The Sugarfree Day 2023 is a wrap

Again sold out and with a lot of sponsors and exhibitors on-site made our day! 2023.10.13

Podcasts and videos drive sales internationally

News 2023.04.17

A total of five international podcasts this spring where our CEO Anders Murman talks ab out ketosis and Acetrack have stirred interest among early adopters aruond the world, including USA, Canada, Australia and New Zeeland

Biohacker Summit Amsterdam

News 2022.10.17

We exhibited our booth live, sold out all Acetracks we had with us and our CEO Anders Murman held a presentation on the main stage in front of 1000+ people.

The Sugarfree day October 12, 2022, successfully conducted

News 2022.10.12

At a full capacity crowd live at Epicenter, Stockholm, and with a record audience on-line, the six speakers drew a lot of attention. See you next year!

Deversify's smart m-health solutions enter the German market

News 2022.04.14

We are delighted to feature on the German-Swedish Chamber of Commerce's website this morning. Thank you for thinking of us, German-Swedish Chamber of Commerce – it has been a joy working with your excellent team.

Deversify and RLVNT sign international distribution agreement

News 2022.03.31

We are pleased to announce that Deversify AB and RLVNT Distribution AB have signed an agreement for distribution in eight European countries for Acetrack, Deversify’s revolutionising solution for non-invasive measurements of metabolic health.

Vinnova grant for a feasibility study

News 2022.03.31

We are pleased to announce that GattyInstruments and Deversify have received a Vinnova grant for a feasibility study into the next generation of microsensors for breathalysers. The aim of the project is to improve MEMS (Micro Electro-Mechanical System) size, speed and price.